Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS

Kadia TM et al. – RAS mutations in acute myeloid leukemia (AML) may delineate a subset of patients who benefit from AraC–based therapy and who may be amenable to treatment with inhibitors of RAS and PI3K signaling pathways.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Medical Student

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Medical Student Articles

Indexed Journals in Medical Student: Academic Medicine, BMC Medical Education, Medical Teachermore